AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$TWST

WERNER ROBERT F. sold $29K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 238 shares of Twist Bioscience Corp (TWST) at $122.62 on 2026-09-08.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Sep 10, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The sale is minor and does not suggest a shift in insider confidence.

02

Market read

Limited relevance; likely no immediate market reaction.

03

What to watch

Potential upcoming earnings or corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 10 2026

Background

Form 4 filings disclose insider trades; investors watch for patterns.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Chief Accounting Officer sold 238 shares for $29,184, a Form 4 filing disclosed on Sep 10, 2026.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is modest relative to holdings and market cap; no 10b5-1 plan indicated.

Market effects

Sector

None; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company developing DNA synthesis platforms.

  • Insider
    Werner Robert F.

    Chief Accounting Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.

timothysykes.com2 min